Standout Papers

Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and e... 2020 2026 2022 2024300
  1. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial (2020)
    Nirav N. Shah, Bryon D. Johnson et al. Nature Medicine

Immediate Impact

1 by Nobel laureates 11 from Science/Nature 59 standout
Sub-graph 1 of 23

Citing Papers

The interaction of innate immune and adaptive immune system
2024 Standout
IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases
2024 Standout
2 intermediate papers

Works of Ashley M. Cunningham being referenced

Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial
2020 Standout

Author Peers

Author Last Decade Papers Cites
Ashley M. Cunningham 194 85 116 307 25 787
Steve Lu 282 84 66 400 24 855
Ayako Inoue 252 45 53 197 47 898
Hongli Sun 279 108 146 246 39 963
Vincenzo Guarcello 278 152 58 108 31 858
Léo Aubert 290 92 61 199 24 846
Brenda J. Gehrke 247 277 81 307 16 798
Lee Shaashua 121 106 24 246 38 906
Joseph M. Valdez 424 173 65 152 20 926
Yuhua Huang 294 136 19 161 36 862
T. Matsuda 200 70 34 100 19 795

All Works

Loading papers...

Rankless by CCL
2026